

Yannick Allanore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5338503/publications.pdf>

Version: 2024-02-01

295
papers

21,415
citations

16451

64
h-index

11607

135
g-index

310
all docs

310
docs citations

310
times ranked

13079
citing authors

#	ARTICLE	IF	CITATIONS
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1747-1755.	0.9	1,705
3	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1809-1815.	0.9	1,017
4	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.9	794
5	Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study. <i>Arthritis and Rheumatism</i> , 2005, 52, 3792-3800.	6.7	656
6	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15002.	30.5	587
7	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	13.7	505
8	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.9	410
9	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine, the</i> , 2020, 8, 963-974.	10.7	348
10	Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. <i>Rheumatology</i> , 2012, 51, 1017-1026.	1.9	345
11	Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1188-1194.	0.9	340
12	<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. <i>New England Journal of Medicine</i> , 2018, 379, 2209-2219.	27.0	326
13	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.7	321
14	Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1355-1360.	0.9	275
15	Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies. <i>Journal of Rheumatology</i> , 2010, 37, 2290-2298.	2.0	259
16	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.9	236
17	High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 58, 284-291.	6.7	225
18	Genome-Wide Scan Identifies TNIP1, PSORS1C1, and RHOB as Novel Risk Loci for Systemic Sclerosis. <i>PLoS Genetics</i> , 2011, 7, e1002091.	3.5	205

#	ARTICLE	IF	CITATIONS
19	The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. <i>Arthritis and Rheumatism</i> , 2009, 60, 1831-1839.	6.7	179
20	Cardiac involvement in systemic sclerosis assessed by tissue Doppler echocardiography during routine care: A controlled study of 100 consecutive patients. <i>Arthritis and Rheumatism</i> , 2008, 58, 1803-1809.	6.7	171
21	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	6.5	170
22	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.9	168
23	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. <i>European Heart Journal</i> , 2017, 38, 2649-2662.	2.2	163
24	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 125-136.	5.6	163
25	Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database. <i>Journal of Rheumatology</i> , 2010, 37, 1488-1501.	2.0	161
26	Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1217-1220.	0.9	160
27	Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 219-227.	0.9	160
28	Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study. <i>PLoS ONE</i> , 2016, 11, e0163894.	2.5	158
29	Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease. <i>Arthritis Research and Therapy</i> , 2011, 13, R166.	3.5	148
30	Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: systematic review and meta-analysis of randomised trials. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1696-1699.	0.9	148
31	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.9	142
32	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.9	132
33	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 96-106.	10.7	118
34	Raynaud phenomenon and digital ulcers in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 208-221.	8.0	115
35	Heart involvement in systemic sclerosis: Evolving concept and diagnostic methodologies. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 46-52.	1.6	112
36	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.9	111

#	ARTICLE	IF	CITATIONS
37	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 299-311.	5.6	110
38	Performance of Candidate Serum Biomarkers for Systemic Sclerosis-associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 972-982.	5.6	101
39	Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1326-1332.	0.9	100
40	GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways. <i>Nature Communications</i> , 2019, 10, 4955.	12.8	100
41	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.9	93
42	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. <i>Journal of Rheumatology</i> , 2017, 44, 639-647.	2.0	93
43	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	3.8	91
44	Vitamin D Deficiency and Insufficiency in 2 Independent Cohorts of Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1924-1929.	2.0	84
45	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 115-123.	3.4	84
46	Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. <i>American Journal of Medicine</i> , 2004, 116, 595-600.	1.5	83
47	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014, 53, 1172-1177.	1.9	83
48	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.9	82
49	Inhibition of activator protein 1 signaling abrogates transforming growth factor β -mediated activation of fibroblasts and prevents experimental fibrosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1642-1652.	6.7	81
50	Trained immunity modulates inflammation-induced fibrosis. <i>Nature Communications</i> , 2019, 10, 5670.	12.8	80
51	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.9	79
52	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	6.2	78
53	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.9	77
54	Articular involvement in systemic sclerosis. <i>Rheumatology</i> , 2012, 51, 1347-1356.	1.9	76

#	ARTICLE	IF	CITATIONS
55	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018, 20, 17.	3.5	75
56	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
57	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1634-1643.	5.6	74
58	Associated Autoimmune Diseases in Systemic Sclerosis Define a Subset of Patients with Milder Disease: Results from 2 Large Cohorts of European Caucasian Patients. <i>Journal of Rheumatology</i> , 2010, 37, 608-614.	2.0	73
59	Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 800-809.	6.7	73
60	Prevalence, Correlates and Outcomes of Gastric Antral Vascular Ectasia in Systemic Sclerosis: A EUSTAR Case-control Study. <i>Journal of Rheumatology</i> , 2014, 41, 99-105.	2.0	73
61	Sequential nailfold videocapillaroscopy examinations have responsiveness to detect organ progression in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 86-94.	3.4	71
62	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.9	71
63	Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. <i>Clinica Chimica Acta</i> , 2006, 365, 143-148.	1.1	69
64	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1600-1607.	0.9	69
65	Increased risk of osteoporosis and fracture in women with systemic sclerosis: A comparative study with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1871-1878.	3.4	68
66	Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. <i>Arthritis Research and Therapy</i> , 2014, 16, R157.	3.5	68
67	Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2175-2183.	0.9	68
68	Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1121-1128.	1.8	67
69	Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1931-1940.	0.9	67
70	Regulatory T Cells in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 2356.	4.8	67
71	Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the <i>TNFAIP3</i> locus as a risk factor for polyautoimmunity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2746-2752.	6.7	63
72	Anticyclic Citrullinated Peptide Antibodies in Rheumatoid and Nonrheumatoid Rheumatic Disorders: Experience with 1162 Patients. <i>Journal of Rheumatology</i> , 2014, 41, 2395-2402.	2.0	63

#	ARTICLE	IF	CITATIONS
73	Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 741-748.	3.4	63
74	Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R55.	3.5	62
75	Systemic sclerosis at the crossroad of polyautoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 1052-1057.	5.8	62
76	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.7	62
77	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	1.9	60
78	Points to consider for skin ulcers in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v67-v71.	1.9	59
79	High prevalence of right ventricular systolic dysfunction in early systemic sclerosis. <i>Journal of Rheumatology</i> , 2004, 31, 1941-5.	2.0	59
80	Lack of Specificity of the 6-Minute Walk Test as an Outcome Measure for Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1481-1485.	2.0	57
81	Genetic basis for systemic sclerosis. <i>Joint Bone Spine</i> , 2007, 74, 577-583.	1.6	56
82	Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1285-1292.	0.9	56
83	Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 149-154.	3.4	55
84	Myocardial contractility is early affected in systemic sclerosis: A Tissue Doppler echocardiography study. <i>European Journal of Echocardiography</i> , 2005, 6, 351-357.	2.3	54
85	Systemic sclerosis: an update in 2008. <i>Joint Bone Spine</i> , 2008, 75, 650-655.	1.6	54
86	Phenotype-Haplotype Correlation of <i>IRF5</i> in Systemic Sclerosis: Role of 2 Haplotypes in Disease Severity. <i>Journal of Rheumatology</i> , 2010, 37, 987-992.	2.0	54
87	Systemic sclerosis: Recent insights. <i>Joint Bone Spine</i> , 2015, 82, 148-153.	1.6	54
88	Cardiac Biomarkers in Systemic Sclerosis: Contribution of High-Sensitivity Cardiac Troponin in Addition to N-terminal Pro-Brain Natriuretic Peptide. <i>Arthritis Care and Research</i> , 2015, 67, 1022-1030.	3.4	54
89	Anti-RNA Polymerase III Antibody Prevalence and Associated Clinical Manifestations in a Large Series of French Patients with Systemic Sclerosis: A Cross-sectional Study. <i>Journal of Rheumatology</i> , 2010, 37, 125-130.	2.0	53
90	Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. <i>Arthritis and Rheumatism</i> , 2011, 63, 2790-2796.	6.7	53

#	ARTICLE	IF	CITATIONS
91	Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 394-399.	0.9	53
92	Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. <i>Arthritis Care and Research</i> , 2012, 64, 1244-1249.	3.4	53
93	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609.	1.9	53
94	Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. <i>Journal of Rheumatology</i> , 2006, 33, 2464-9.	2.0	53
95	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	5.0	52
96	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.9	51
97	OX40L blockade protects against inflammation-driven fibrosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3901-10.	7.1	50
98	New therapeutic strategies in the management of systemic sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 607-615.	1.8	49
99	Association of a <i>KCNK5</i> gene polymorphism with systemic sclerosis-associated pulmonary arterial hypertension in the European Caucasian population. <i>Arthritis and Rheumatism</i> , 2010, 62, 3093-3100.	6.7	49
100	Cardiovascular disease in rheumatoid arthritis: Single-center hospital-based cohort study in France. <i>Joint Bone Spine</i> , 2007, 74, 66-72.	1.6	48
101	Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 162-170.	5.6	48
102	Autoantibodies against Endothelin 1 Type A Receptor Are Strong Predictors of Digital Ulcers in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1801-1807.	2.0	46
103	C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: Results from a large french cohort and meta-analysis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2091-2096.	6.7	45
104	Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. <i>Arthritis Research</i> , 2004, 6, R309.	2.0	43
105	Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database. <i>Autoimmunity Reviews</i> , 2020, 19, 102452.	5.8	43
106	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.7	43
107	Evaluation of interleukin 13 polymorphisms in systemic sclerosis. <i>Immunogenetics</i> , 2006, 58, 693-699.	2.4	42
108	Endothelial progenitor cells and rheumatic disorders. <i>Joint Bone Spine</i> , 2008, 75, 131-137.	1.6	42

#	ARTICLE	IF	CITATIONS
109	Genetic background of systemic sclerosis: autoimmune genes take centre stage. <i>Rheumatology</i> , 2010, 49, 203-210.	1.9	42
110	Trabecular Bone Score in Female Patients with Systemic Sclerosis: Comparison with Rheumatoid Arthritis and Influence of Glucocorticoid Exposure. <i>Journal of Rheumatology</i> , 2015, 42, 228-235.	2.0	42
111	Systemic sclerosis trial design moving forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 177-180.	1.7	42
112	Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls". <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 79-85.	3.4	42
113	A genetic variation located in the promoter region of the <i>UPAR</i> (<i>CD87</i>) gene is associated with the vascular complications of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 247-256.	6.7	41
114	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 191-197.	0.9	41
115	Identification of <i>NF-κB</i> and <i>PLCL2</i> as new susceptibility genes and highlights on a potential role of <i>IRF8</i> through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	3.5	41
116	Circulating lung biomarkers in idiopathic lung fibrosis and interstitial lung diseases associated with connective tissue diseases: Where do we stand?. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 480-491.	3.4	41
117	Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro-Osteolysis in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 366-373.	3.4	40
118	T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 197.	3.5	40
119	<i>IL13RA2</i> gene polymorphisms are associated with systemic sclerosis. <i>Journal of Rheumatology</i> , 2006, 33, 2015-9.	2.0	40
120	The genetics of systemic sclerosis: an update. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S75-86.	0.8	40
121	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.9	39
122	Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. <i>Current Opinion in Rheumatology</i> , 2008, 20, 697-702.	4.3	38
123	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1541-1549.	0.9	38
124	Comparison of Pain, Pain Burden, Coping Strategies, and Attitudes Between Patients with Systemic Sclerosis and Patients with Rheumatoid Arthritis: A Cross-Sectional Study. <i>Pain Medicine</i> , 2013, 14, 1776-1785.	1.9	37
125	French recommendations for the management of systemic sclerosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 322.	2.7	37
126	Independent Replication and Metaanalysis of Association Studies Establish <i>TNFSF4</i> as a Susceptibility Gene Preferentially Associated with the Subset of Anticentromere-positive Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2012, 39, 997-1003.	2.0	35

#	ARTICLE	IF	CITATIONS
127	Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1089-1098.	0.9	35
128	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. <i>RMD Open</i> , 2019, 5, e000826.	3.8	35
129	Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1736-1740.	0.9	34
130	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 686-693.	3.4	34
131	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	3.9	34
132	The clinical phenotype of systemic sclerosis patients with anti-PM/Scl antibodies: results from the EUSTAR cohort. <i>Rheumatology</i> , 2021, 60, 5028-5041.	1.9	34
133	Evidence for caveolin-1 as a new susceptibility gene regulating tissue fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1034-1041.	0.9	33
134	An international Survey on non-invasive techniques to assess the microcirculation in patients with Raynaud's phenomenon (SUNSHINE survey). <i>Rheumatology International</i> , 2017, 37, 1879-1890.	3.0	33
135	The need for a holistic approach for SSc-ILD " achievements and ambiguity in a devastating disease. <i>Respiratory Research</i> , 2020, 21, 197.	3.6	33
136	Safety and effectiveness of abatacept in systemic sclerosis: The EUSTAR experience. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1489-1493.	3.4	33
137	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.9	31
138	IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. <i>European Respiratory Journal</i> , 2019, 54, 1900154.	6.7	31
139	Systemic sclerosis: Recent insight in clinical management. <i>Joint Bone Spine</i> , 2020, 87, 293-299.	1.6	31
140	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , 2015, 54, 144-151.	1.9	30
141	Targeting Costimulatory Pathways in Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2018, 9, 2998.	4.8	30
142	Systemic sclerosis pathogenesis: contribution of recent advances in genetics. <i>Current Opinion in Rheumatology</i> , 2020, 32, 505-514.	4.3	30
143	Association of hypoxia-inducible factor 1A (<i>HIF1A</i>) gene polymorphisms with systemic sclerosis in a French European Caucasian population. <i>Scandinavian Journal of Rheumatology</i> , 2009, 38, 291-294.	1.1	29
144	Use of biologics and other novel therapies for the treatment of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 469-482.	3.0	29

#	ARTICLE	IF	CITATIONS
145	Effects of successive switches to different biosimilars infliximab on immunogenicity in chronic inflammatory diseases in daily clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1449-1456.	3.4	29
146	Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. <i>Arthritis Research</i> , 2005, 7, R93.	2.0	28
147	Skin Telangiectasia and the Identification of a Subset of Systemic Sclerosis Patients With Severe Vascular Disease. <i>Arthritis Care and Research</i> , 2016, 68, 1021-1027.	3.4	28
148	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018, 4, e000757.	3.8	28
149	Muscle involvement in systemic sclerosis: points to consider in clinical trials. <i>Rheumatology</i> , 2017, 56, v38-v44.	1.9	27
150	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. <i>Rheumatology</i> , 2020, 59, 1684-1694.	1.9	27
151	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1049-1058.	5.6	27
152	Insights into the pathogenesis of systemic sclerosis based on the gene expression profile of progenitor-derived endothelial cells. <i>Arthritis and Rheumatism</i> , 2011, 63, 3552-3562.	6.7	26
153	Brief Report: A Regulatory Variant in <i>CCR6</i> Is Associated With Susceptibility to Antitopoisomerase-Positive Systemic Sclerosis. <i>Arthritis and Rheumatism</i> , 2013, 65, 3202-3208.	6.7	26
154	Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease. <i>PLoS ONE</i> , 2020, 15, e0232978.	2.5	26
155	Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population. <i>Rheumatology</i> , 2015, 54, 1262-1269.	1.9	25
156	Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 537-543.	3.4	25
157	Soluble CD163 as a Potential Biomarker in Systemic Sclerosis. <i>Disease Markers</i> , 2018, 2018, 1-5.	1.3	25
158	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.7	25
159	Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. <i>Journal of Rheumatology</i> , 2003, 30, 68-73.	2.0	25
160	Familial Autoimmunity in Systemic Sclerosis – Results of a French-based Case-Control Family Study. <i>Journal of Rheumatology</i> , 2012, 39, 532-538.	2.0	24
161	Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e19-e19.	0.9	24
162	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR- γ) gene and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 128.	3.5	24

#	ARTICLE	IF	CITATIONS
163	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1040-1047.	0.9	24
164	Epistatic Interaction between BANK1 and BLK in Rheumatoid Arthritis: Results from a Large Trans-Ethnic Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e61044.	2.5	24
165	Lack of association of eNOS (G894T) and p22phox NADPH oxidase subunit (C242T) polymorphisms with systemic sclerosis in a cohort of French Caucasian patients. <i>Clinica Chimica Acta</i> , 2004, 350, 51-55.	1.1	23
166	Combination of Echocardiographic and Pulmonary Function Test Measures Improves Sensitivity for Diagnosis of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Analysis of 2 Cohorts. <i>Journal of Rheumatology</i> , 2013, 40, 1706-1711.	2.0	23
167	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 439-445.	3.4	23
168	Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2020, 47, 249-254.	2.0	23
169	Association Study of <i>ITGAM</i> , <i>ITGAX</i> and <i>CD58</i> Autoimmune Risk Loci in Systemic Sclerosis: Results from 2 Large European Caucasian Cohorts. <i>Journal of Rheumatology</i> , 2011, 38, 1033-1038.	2.0	22
170	Enhanced expression of ephrins and thrombospondins in the dermis of patients with early diffuse systemic sclerosis: potential contribution to perturbed angiogenesis and fibrosis. <i>Rheumatology</i> , 2011, 50, 1494-1504.	1.9	21
171	Nintedanib in Patients With Systemic Sclerosis-associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. <i>Arthritis and Rheumatology</i> , 2022, 74, 518-526.	5.6	21
172	Treatment of systemic sclerosis. <i>Joint Bone Spine</i> , 2006, 73, 363-368.	1.6	20
173	Limited cutaneous systemic sclerosis: the unfairly neglected subset. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 241-246.	1.7	20
174	Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database. <i>Arthritis Research and Therapy</i> , 2020, 22, 257.	3.5	20
175	Early trajectories of skin thickening are associated with severity and mortality in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2020, 22, 30.	3.5	20
176	Genomic Risk Score impact on susceptibility to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 118-127.	0.9	20
177	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 239-261.	6.5	20
178	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.8	20
179	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
180	Advances in cohort enrichment shape future of trial design. <i>Nature Reviews Rheumatology</i> , 2015, 11, 72-74.	8.0	19

#	ARTICLE	IF	CITATIONS
181	Outcome of Patients with Systemic Sclerosis in the Intensive Care Unit. <i>Journal of Rheumatology</i> , 2015, 42, 1406-1412.	2.0	19
182	Treatment of systemic sclerosis: is there any hope for the future?: Table 1. <i>RMD Open</i> , 2016, 2, e000260.	3.8	19
183	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , 2019, 21, 130.	3.5	19
184	Decreased expression of the endothelial cell-derived factor EGFL7 in systemic sclerosis: potential contribution to impaired angiogenesis and vasculogenesis. <i>Arthritis Research and Therapy</i> , 2013, 15, R165.	3.5	18
185	Flare of calcinosis despite rituximab therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, e5-e6.	3.4	18
186	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 169-182.	1.7	18
187	Natural variability in the disease course of SSc-ILD: implications for treatment. <i>European Respiratory Review</i> , 2021, 30, 200340.	7.1	18
188	Experimental models of dermal fibrosis and systemic sclerosis. <i>Joint Bone Spine</i> , 2013, 80, 23-28.	1.6	17
189	Role of Stromelysin 2 (Matrix Metalloproteinase 10) as a Novel Mediator of Vascular Remodeling Underlying Pulmonary Hypertension Associated With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2209-2221.	5.6	17
190	Association between Rheumatoid Arthritis and Pulmonary Hypertension: Data from the French Pulmonary Hypertension Registry. <i>Respiration</i> , 2018, 95, 244-250.	2.6	17
191	¹⁸ F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.9	17
192	Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study. <i>Rheumatology</i> , 2022, 61, 2755-2769.	1.9	17
193	Updating the genetics of systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 665-670.	4.3	16
194	N-terminal pro-brain natriuretic peptide is a strong predictor of mortality in systemic sclerosis. <i>International Journal of Cardiology</i> , 2016, 223, 385-389.	1.7	16
195	Angiotensin-Converting Enzyme Gene Does Not Contribute to Genetic Susceptibility to Systemic Sclerosis in European Caucasians. <i>Journal of Rheumatology</i> , 2009, 36, 337-340.	2.0	15
196	Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. <i>Journal of Rheumatology</i> , 2017, 44, 1011-1017.	2.0	15
197	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	5.6	15
198	Interstitial pneumonia with autoimmune features: a new classification still on the move. <i>European Respiratory Review</i> , 2018, 27, 180047.	7.1	15

#	ARTICLE	IF	CITATIONS
199	Estrogens Counteract the Profibrotic Effects of TGF- β 2 and their Inhibition Exacerbates Experimental Dermal Fibrosis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 593-601.e7.	0.7	15
200	Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1579-1588.	5.6	15
201	Targeting CD226/DNAX accessory molecule-1 (DNAM-1) in collagen-induced arthritis mouse models. <i>Journal of Inflammation</i> , 2015, 12, 9.	3.4	14
202	Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1032-1038.	0.9	14
203	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. <i>Rheumatology</i> , 2020, 59, 2016-2023.	1.9	14
204	Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 85-100.	3.0	14
205	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 61-71.	1.7	14
206	Myocardial dysfunction in rheumatoid arthritis: a controlled tissue-Doppler echocardiography study. <i>Journal of Rheumatology</i> , 2007, 34, 2005-9.	2.0	14
207	The Nuclear Receptor Constitutive Androstane Receptor/NR1H3 Enhances the Profibrotic Effects of Transforming Growth Factor β 2 and Contributes to the Development of Experimental Dermal Fibrosis. <i>Arthritis and Rheumatology</i> , 2014, 66, 3140-3150.	5.6	13
208	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	3.4	13
209	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. <i>Rheumatology</i> , 2017, 56, 844-852.	1.9	13
210	Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1681-1685.	0.9	13
211	Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 891-900.	0.9	13
212	Ethnic influence on the phenotype of French patients with systemic sclerosis. <i>Joint Bone Spine</i> , 2021, 88, 105081.	1.6	13
213	Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. <i>Arthritis Research and Therapy</i> , 2021, 23, 119.	3.5	13
214	Driving Role of Interleukin-2-Related Regulatory ζ + T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2022, 74, 1387-1398.	5.6	13
215	Incomplete thymic involution in systemic sclerosis and rheumatoid arthritis. <i>Joint Bone Spine</i> , 2013, 80, 48-51.	1.6	12
216	Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. <i>Lancet Rheumatology</i> , The, 2020, 2, e173-e184.	3.9	12

#	ARTICLE	IF	CITATIONS
217	Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1339-1347.	3.4	12
218	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.7	12
219	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA Dermatology</i> , 2021, 157, 851-858.	4.1	12
220	Patient phenotypes in fibromyalgia comorbid with systemic sclerosis or rheumatoid arthritis: influence of diagnostic and screening tests. Screening with the FIRST questionnaire, diagnosis with the ACR 1990 and revised ACR 2010 criteria. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 105, 35-42.	0.8	12
221	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	1.9	11
222	Hemodynamic changes after acute fluid loading in patients with systemic sclerosis without pulmonary hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-6.	1.7	11
223	Dyspnoea and cough in patients with systemic sclerosis – associated interstitial lung disease in the SENSICIS trial. <i>Rheumatology</i> , 2022, 61, 4397-4408.	1.9	11
224	Usefulness of routine electrocardiography for heart disease screening in patients with spondyloarthritis or rheumatoid arthritis. <i>Joint Bone Spine</i> , 2010, 77, 146-150.	1.6	10
225	Dermal tissue and cellular expression of fibrillin-1 in diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2010, 49, 657-661.	1.9	10
226	Association Study of Serotonin Transporter Gene (SLC6A4) in Systemic Sclerosis in European Caucasian Populations. <i>Journal of Rheumatology</i> , 2010, 37, 1164-1167.	2.0	10
227	Small, medium but not large arteries are involved in digital ulcers associated with systemic sclerosis. <i>Joint Bone Spine</i> , 2016, 83, 444-447.	1.6	10
228	The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study. <i>Rheumatology</i> , 2017, 56, 1874-1883.	1.9	10
229	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerID) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 507-515.	0.9	10
230	Nailfold capillaroscopy in SSc: innocent bystander or promising biomarker for novel severe organ involvement/progression?. <i>Rheumatology</i> , 2022, 61, 4384-4396.	1.9	10
231	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. <i>Rheumatology</i> , 2017, 56, v23-v26.	1.9	9
232	TNF receptor-associated periodic syndrome (TRAPS): A new cause of joint destruction?. <i>Joint Bone Spine</i> , 2009, 76, 567-569.	1.6	8
233	All-cause Mortality Associated with TNF- α Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Medicine</i> , 2015, 128, 1367-1373.e1.	1.5	8
234	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. <i>Arthritis Research and Therapy</i> , 2022, 24, 19.	3.5	8

#	ARTICLE	IF	CITATIONS
235	Usefulness of Multidetector Computed Tomography to Assess Calcinosis in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2008, 35, 2274-2275.	2.0	7
236	A very rare cause of acro-osteolysis: Hajdu-Cheney syndrome. <i>Joint Bone Spine</i> , 2015, 82, 455-459.	1.6	7
237	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 66-76.	1.7	7
238	Erosive arthritis autoantibodies in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151947.	3.4	7
239	Early phase clinical and biological markers associated with subclinical atherosclerosis measured at 7 years of evolution in an early inflammatory arthritis cohort. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 58-67.	0.8	7
240	Cardiovascular mortality in patients with inflammatory rheumatic disorders. <i>Joint Bone Spine</i> , 2007, 74, 120-122.	1.6	6
241	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , 2017, 56, v12-v16.	1.9	6
242	Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 96-102.	1.9	6
243	Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 111-117.	1.7	6
244	Acazicolcept (ALPN-101), a dual ICOS/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models. <i>Arthritis Research and Therapy</i> , 2022, 24, 13.	3.5	6
245	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. <i>Rheumatology</i> , 2022, 61, 4035-4046.	1.9	6
246	Performance of Skin Ultrasound to Measure Skin Involvement in Different Animal Models of Systemic Sclerosis. <i>Ultrasound in Medicine and Biology</i> , 2013, 39, 845-852.	1.5	5
247	Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 149-159.	1.7	5
248	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	3.0	5
249	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. <i>Rheumatology</i> , 2022, 61, 743-755.	1.9	5
250	Quality of life in SSc-ILD patients: Understanding the impact of the ILD and the needs of the SSc-ILD patients and their need for caregivers in France. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 49-56.	1.7	5
251	From VEDOSS to established systemic sclerosis diagnosis according to ACR/EULAR 2013 classification criteria: a French-Italian capillaroscopic survey. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 82-87.	0.8	5
252	Systemic Sclerosis. <i>European Medical Journal Rheumatology</i> , 0, , 100-109.	0.0	4

#	ARTICLE	IF	CITATIONS
253	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.8	4
254	Phosphodiesterase 5 inhibitors in vascular systemic disorders. <i>Joint Bone Spine</i> , 2012, 79, 338-340.	1.6	3
255	Effect of endothelin-1 receptor antagonists on skin fibrosis in scleroderma patients from the EUSTAR database. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 220-225.	1.7	3
256	Ochronosis of the spine mimicking ankylosing spondylitis successfully treated with anakinra. <i>Joint Bone Spine</i> , 2020, 87, 368-369.	1.6	3
257	Successful treatment of severe interstitial pneumonia by removal of circulating autoantibodies: a case series. <i>BMC Pulmonary Medicine</i> , 2021, 21, 13.	2.0	3
258	Multiple spontaneous visceral hematomas revealing polyarteritis nodosa. <i>Journal of Rheumatology</i> , 2004, 31, 1858-60.	2.0	3
259	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 68-75.	0.8	3
260	Spleen Calcifications in Connective Tissue Disorders. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 41, e1-e2.	3.4	2
261	Association study of CRP gene in systemic sclerosis in European Caucasian population. <i>Rheumatology International</i> , 2014, 34, 389-392.	3.0	2
262	OP0183...EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , ,		2
263	Stem cells: Hope for systemic sclerosis patients?. <i>Joint Bone Spine</i> , 2020, 87, 285-288.	1.6	2
264	Rapidly Progressive Systemic Sclerosis-associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Guérin Therapy for Early-stage Bladder Cancer. <i>Journal of Rheumatology</i> , 2021, 48, 1348-1349.	2.0	2
265	An update on recent randomized clinical trials in systemic sclerosis. <i>Joint Bone Spine</i> , 2021, 88, 105184.	1.6	2
266	Pulmonary arterial hypertension occurrence after liver transplant in systemic sclerosis: a report of 2 cases sustainably treated by sildenafil. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S53-4.	0.8	2
267	Is sitaxsentan a good therapeutic option for pulmonary arterial hypertension associated with connective tissue disease?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 238-239.	3.2	1
268	Description d'une nouvelle mutation de LRP5 chez un patient atteint d'un syndrome ostéoporose-pseudogliome. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2010, 77, 179-181.	0.0	1
269	Avancées thérapeutiques dans l'atteinte interstitielle pulmonaire au cours de la sclérodémie systémique. <i>Revue Du Rhumatisme Monographies</i> , 2018, 85, 165-170.	0.0	1
270	OP0239...PROGRESSIVE LUNG FIBROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE IN THE EUSTAR DATABASE. , ,		1

#	ARTICLE	IF	CITATIONS
271	OP0227â€¦EFFECTS OF SUCCESSIVE SWITCHES TO DIFFERENT BIOSIMILARS INFLIXIMAB ON IMMUNOGENICITY IN CHRONIC INFLAMMATORY DISEASES IN DAILY CLINICAL PRACTICE. , 2019, , .		1
272	OP0065â€¦THE VERY EARLY DIAGNOSIS OF SYSTEMIC SCLEROSIS (VEDOSS) PROJECT: PREDICTORS TO DEVELOP DEFINITE DISEASE FROM AN INTERNATIONAL MULTICENTRE STUDY. , 2019, , .		1
273	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 43-48.	0.8	1
274	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 114-121.	0.8	1
275	SclÃ©rodermie systÃ©mique: Ã©tat des lieux en 2008. Revue Du Rhumatisme (Edition Francaise), 2008, 75, 918-924.	0.0	0
276	Le TNF Receptor-Associated Periodic Syndrome (TRAPS)Â: nouvelle cause dâ€™atteinte articulaire Ã©rosiveÂ?. Revue Du Rhumatisme (Edition Francaise), 2009, 76, 918-921.	0.0	0
277	GÃ©nÃ©tique et physiopathologie de la sclÃ©rodermie systÃ©mique. Bulletin De L'Academie Nationale De Medecine, 2011, 195, 55-67.	0.0	0
278	Systemic Sclerosis-related Acute Myocardial Infarction: Definition. American Journal of Medicine, 2014, 127, e37.	1.5	0
279	Une cause rare dâ€™acro-ostÃ©olyse: le syndrome de Hadju-Cheney. Revue Du Rhumatisme (Edition) Tj ETQq1 1,0,784314,rgBT /O	0.0	0
280	Dr. PÃ©ne, <i>et al</i> reply. Journal of Rheumatology, 2016, 43, 677-677.	2.0	0
281	Reply. Arthritis and Rheumatology, 2019, 71, 1204-1206.	5.6	0
282	FRI0303â€¦THE EFFECTS OF RIOCIQUAT ON RAYNAUDâ€™S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		0
283	FRI0325â€¦IDENTIFYING SYSTEMIC SCLEROSIS PATIENTS AT RISK OF PROGRESSIVE LUNG FIBROSIS â€œ A EUSTAR DATABASE ANALYSIS. , 2019, , .		0
284	SAT0273â€¦PREDICTIVE VALUE OF THE REVISED EUROPEAN SCLERODERMA TRIALS AND RESEARCH GROUP ACTIVITY INDEX (EUSTAR-AI). , 2019, , .		0
285	SAT0254â€¦VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
286	Ãšlceras digitales en esclerosis sistÃ©mica. Revista Colombiana De ReumatologÃ­a, 2020, 27, 26-35.	0.1	0
287	Digital ulcers in systemic sclerosis. Revista Colombiana De ReumatologÃ­a (English Edition), 2020, 27, 26-35.	0.0	0
288	DonnÃ©es rÃ©centes sur la prise en charge clinique de la sclÃ©rodermie systÃ©mique. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 24-31.	0.0	0

#	ARTICLE	IF	CITATIONS
289	Influence de l'origine ethnique sur le phénotype de patients atteints de sclérodémie systémique en France. Revue Du Rhumatisme (Edition Francaise), 2021, 89, 176-176.	0.0	0
290	Revue des récents essais randomisés dans la sclérodémie systémique. Revue Du Rhumatisme (Edition) Tj, 2021, 89, 176-176.	0.0	0
291	A Diffuse Scleroderma Patient Who Presents with Shortness of Breath and Enlarged Cardiac Silhouette. , 2011, , 139-145.		0
292	Genetic Factors. , 2017, , 25-38.		0
293	Digital Ulcers, Vasculopathy and Internal Organ Involvement. , 2019, , 79-85.		0
294	The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110666.	2.7	0
295	Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome. Clinical and Experimental Rheumatology, 2021, 39 Suppl 131, 163-164.	0.8	0